Careteq Limited (ASX: CTQ) (“Careteq” or “the Company”), a clinical healthtech company specialising in innovative medication management and clinical governance solutions, is pleased to provide the following quarterly update and commentary on its Appendix 4C for the quarter ending 30 September 2025.
Careteq is pleased to release its unaudited preliminary full year results for the period ended 30 June 2025 (“FY25”): Revenue up 5.4% and Group EBITDA up 171% from Continuing Operations
Careteq is pleased to release its Q4 FY25 Activities Report and Appendix 4C: Platform Integration Nears Completion, Revenue Growth Exceeds Projections, and Strategic Partnerships Expand
Careteq is pleased to release its Q3 FY25 Activities Report and Appendix 4C: Platform Integration Nears Completion, Revenue Growth Exceeds Projections, and Strategic Partnerships Expand
Careteq is pleased to release its FY25 Interim Results Presentation.
Careteq’s 1H FY25 Results show Maiden EBITDA profit achieved ahead of target
MedicAlert Foundation and Careteq Announce Strategic Partnership to Enhance Medication Safety for Australians.
Careteq Limited (ASX: CTQ, “Careteq” or the “Group”), is pleased to release its 2024 AGM Presentation.
Careteq Limited (ASX: CTQ, “Careteq” or the “Group”), is pleased to release its 2024 Annual Report.
Careteq Limited (ASX: CTQ, “Careteq” or the “Group”), steamlines operations to focus on medication management.